Wave Life Sciences Ltd. - 8-K Filing
Wave Life Sciences announced positive clinical data from its RestorAATion-2 trial for WVE-006 in treating alpha-1 antitrypsin deficiency (AATD). The drug achieved MZ-like phenotype levels, with wild-type AAT comprising up to 64% of total AAT and a reduction of harmful Z-AAT by 71%. Wave expects regulatory feedback on potential accelerated approval mid-2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $WVE